Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 11, 2011, Pages 1482-1485

  Attia, Fadia M ^a   Maaty, Ahmed ^a   Kalil, Fawzy Attia ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 82555205406     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0731-OA     Document Type: Article

References (28)

1. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus- an independent risk factor for endothelial dysfunction in women. Circulation. 2004; 110(4): 399-404. (Pubitemid 38993848)
2. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10): 2331-2337. (Pubitemid 32977500)
3. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60(2): 221-225.
4. Pearson JD. Normal endothelial cell function. Lupus. 2000; 9(3): 183-188. (Pubitemid 30199260)
5. Johnson SR, Harvery PJ, Floras JS, et al. Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus. 2004; 13(8): 590-593. (Pubitemid 39145488)
6. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology. 2007; 46(6): 983-988. (Pubitemid 47062508)
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.
8. Ionescu R. Lupusul eritematos sistemic. In: Ionescu R. Esenţialul ˆn reumatologie. a 2-a ed. Bucureşti, Romania: Editura Medicala Amaltea; 2007: 348-371.
9. Yazici ZA, Raschi E, Patel A, et al. Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immunol. 2001; 13(3): 349-357. (Pubitemid 32179083)
10. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007; 34(1): 70-75. (Pubitemid 46106565)
11. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost. 2003; 90(5): 915-920. (Pubitemid 37427862)
12. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol. 2004; 15(1): 139-145. (Pubitemid 38139616)
13. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol. 2000; 62(2): 15-20.
14. Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep. 2000; 2(1): 39-43.
15. Hunting CR, Noort WA, Zwaginga JJ. Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. Vox Sang. 2005; 88(1): 1-9.
16. Mutin M, Canavy I, Blann A. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. 1999; 93(2): 2951-2958. (Pubitemid 29200786)
17. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Bayon J. Circulating activated endothelial cells in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(5): 1203-1208.
18. Blann A.D., Woywodt A, Bertolini F, et al. Circulating endothelial cells: biomarker of vascular disease. Thromb Haemost. 2005; 93(2): 228-235. (Pubitemid 40253726)
19. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med. 2004; 89(6): 294-300. (Pubitemid 44145493)
20. Blann A.D. Endothelial cell activation, injury, damage, and dysfunction: separate entity or mutual terms. Blood Coagul Fibrinolysis. 2000; 11(2): 623-630.
21. Tani C, Mosca M, d'Ascanio A, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo. 2006; 58(3): 212-218. (Pubitemid 44450248)
22. Manzi S, Meilahn EN, Rairie JE. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997; 145(5): 408-415. (Pubitemid 27084212)
23. Turner E, Dishy V, Chung C.P., et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification Vasc Health Risk Manag. 2005; 1(4): 357-360.
24. Bhatt SP, Handa R, Gulti GS, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol. 2006; 35(1): 128-132.
25. Lima DS, Sato EI, Lima VC, et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002; 29(2): 292-297. (Pubitemid 34118776)
26. Piper MK, Raza K, Nuttall SL, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus. 2007; 16(2): 84-88. (Pubitemid 46347929)
27. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004; 103(10): 3677-3683. (Pubitemid 38596281)
28. Rabascio C, Muratori E, Mancuso P, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004; 64(12): 4373-4377. (Pubitemid 38802446)